Activity of Meropenem with a Novel Broader-Spectrum β-lactamase Inhibitor WCK 4234 against Gram-Negative Pathogens Endemic to New York City.
WCK 4234 is a novel diazabicyclooctane with potent inhibitory activity against class A and D carbapenemases and class C enzymes. We examined the in vitro activity of meropenem + WCK 4234 (4 or 8 μg/ml) against Gram-negative pathogens from New York City. Three groups were analyzed: a contemporary collection of isolates, a collection of known carbapenem-resistant isolates, and a collection of isolates with defined resistance mechanisms. From the contemporary collection, 1) all Enterobacteriaceae were susceptible to meropenem + WCK 4234, 2) susceptibility rates for Acinetobacter baumannii to meropenem alone were 56.5%, with WCK 4234 4 μg/ml 82.6%, and with WCK 4234 8 μg/ml 95.7%, and 3) WCK 4234 had modest effect on susceptibility for P. aeruginosa Against a collection of carbapenem-resistant isolates, WCK 4234 added to meropenem 1) restored meropenem susceptibility against KPC-producing K. pneumoniae, 2) improved susceptibility against A. baumannii, and 3) had a negligible effect for P. aeruginosa When tested against isolates with defined mechanisms of resistance, K. pneumoniae with bla KPC had higher meropenem + WCK 4234 MICs albeit well below the susceptibility breakpoint; efflux systems or porins did not correlate with susceptibility. For A. baumannii, MICs of meropenem + WCK 4234 did not correlate with efflux systems, outer membrane protein, bla ampC or bla oxa-51, however MICs were higher in isolates with ESBLs. For P. aeruginosa, isolates with relatively higher MICs to meropenem + WCK 4234 had increased expression of ampC WCK 4234 is a potent β-lactamase inhibitor that when combined with meropenem, displays promising activity against multidrug-resistant pathogens.